Alphamab Oncology (09966) disclosed that on 28 October 2025, 320,000 ordinary shares were repurchased on the Hong Kong Stock Exchange. The highest repurchase price per share reached HKD 11.97, with the lowest at HKD 11.53, amounting to an aggregate paid sum of approximately HKD 3.77 million.

After this repurchase, the number of issued shares (excluding treasury shares) decreased to 970,074,697, while treasury shares increased to 4,073,000. The overall total of issued shares remained at 974,147,697. The repurchase was carried out under a mandate granted on 12 June 2025, which authorized the repurchase of up to 96,218,980 shares. Cumulatively, the company has repurchased 1,121,000 shares under this authority, representing around 0.1165% of the issued shares (excluding treasury shares) at the time the mandate was granted.